Skip to Content
CQM Home
Main Content

BioXmark Liquid Fiducial Marker

This product information is intended for markets outside the U.S. Bioxmark is manufactured by Nanovi.
 

Customizable Implantation
The liquid nature of BioXmark enables implantation of multiple markers of varying sizes in the same uninterrupted procedure.

Positional Stability and Visibility
Following implantation, sticky and soft markers form, adapting to the surrounding tissue and remaining visible under relevant imaging, including MRI.

Workflow Benefts
Achieve CT and MRI image acquisitions while ensuring streamlined workflows and low risk of complications, all without specialized equipment.

Photon and Proton Compatibility
BioXmark markers are non-metallic and have low levels of artifacts and low-dose perturbation. These qualities support precise treatment planning and image-guided treatment, including proton therapy.

BioXmark is indicated for use to radiographically mark soft tissue (bladder, esophagus, liver, lung, lymph nodes, rectal, stomach, pancreas, head & neck).

Find a Product That Fits Your Needs

Add to QuoteProductDescription
BioXmark Liquid Fiducial Marker, 5 x 1 mL (Denmark, Norwegian, Sweden, Finland), 5 bottles
BioXmark Liquid Fiducial Marker, 5 x 1 mL (United Kingdom, Germany, Netherlands, France, Luxembourg, Ireland, Liechtenstein, Belgium, Austria, Iceland, Malta, Switzerland), 5 bottles
BioXmark Liquid Fiducial Marker, 5 x 1 mL (Spain, Italy), 5 bottles
11110510
BioXmark Liquid Fiducial Marker, 5 x 1 mL (Denmark, Norwegian, Sweden, Finland), 5 bottles
11110515
BioXmark Liquid Fiducial Marker, 5 x 1 mL (United Kingdom, Germany, Netherlands, France, Luxembourg, Ireland, Liechtenstein, Belgium, Austria, Iceland, Malta, Switzerland), 5 bottles
11110520
BioXmark Liquid Fiducial Marker, 5 x 1 mL (Spain, Italy), 5 bottles


This team's "Recent clinical studies have shown that the use of liquid fiducial markers has significantly improved treatment outcomes for patients with these tumors. Those treated with this technology have experienced a 30% reduction in treatment times and a 20% decrease in side effects compared to traditional methods. The adoption of liquid fiducial markers in clinical practice represents a major innovation in the field of radiotherapy."

DR. RITA MARINA NIESPOLO, IRCCS SAN GERARDO DEI TINTORI FOUNDATION, ITALY

 FONDAZIONE IRCCS SAN GERARDO DEI TINTORI